Health
Excel
Zoonotic Diseases Dataset – Animal-to-Human Infectious Diseases
Zoonotic Diseases Dataset
The Zoonotic Diseases Dataset is a structured medical database containing a comprehensive list of diseases that can be transmitted from animals to humans.
Zoonotic diseases are a major focus of global health due to their role in outbreaks and pandemics. These diseases can be caused by viruses, bacteria, parasites, and fungi, and are often transmitted through direct contact with animals, insect vectors, or contaminated environments.
This dataset provides organised information about zoonotic diseases, helping researchers, epidemiologists, and healthcare professionals analyse transmission patterns, risk factors, and disease characteristics.
Each record includes detailed clinical information such as disease descriptions, transmission methods, affected systems, common symptoms, severity levels, and treatment approaches.
The dataset has been cleaned and structured for easy integration into spreadsheets, databases, and analytical tools.
It is ideal for global health researchers, epidemiologists, healthcare developers, and data scientists working with infectious disease data.
Dataset Contents
The dataset includes fields such as:
- Disease Name
- Pathogen Type (Viral / Bacterial / Parasitic / Fungal)
- Animal Source / Reservoir
- Transmission Method
- Common Symptoms
- Severity Level
- Affected Body System
- Treatment / Management
Example Diseases Included
- Rabies
- Lyme Disease
- Ebola Virus Disease
- Avian Influenza
- Salmonellosis
- Leptospirosis
- Plague
- Brucellosis
- Toxoplasmosis
- West Nile Virus
...and many more zoonotic diseases.
Data Preview
17 columns
25 rows shown
| ID | Disease Name | Category | Prevalence | Inheritance Pattern | Affected Gene(s) | Chromosome Location | Key Symptoms | Typical Age of Onset | Diagnosis Methods | Available Treatments | Orphan Drug Designation | ICD-10 Code | OMIM Number | Affected System | Disease Severity | Life Expectancy Impact | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 1 | Rabies (Classical, Dog-mediated) | Viral Zoonosis | ~59,000 human deaths/yr globally (mostly Asia/Africa) | Acquired (Lyssavirus - bite/scratch from infected mammal, mainly dogs) | N/A | N/A | Prodrome (fever, paresthesia at bite), encephalitic (hydrophobia, aerophobia, agitation) or paralytic form, near-100% fatal once symptomatic | All ages | Clinical + exposure history; antemortem RT-PCR (saliva, skin biopsy nape), Negri bodies postmortem, RFFIT serology | Post-exposure prophylaxis: wound washing + RIG + 4-dose vaccine (Essen/Zagreb); pre-exposure vaccine for high-risk; supportive care if symptomatic (Milwaukee protocol rare) | No | A82.9 | N/A | Central nervous system | Severe | Reduced (>99% fatal once symptomatic) |
| 2 | 2 | Rabies (Sylvatic - Bat/Wildlife) | Viral Zoonosis | Most US cases bat-related; raccoon, fox, skunk in wildlife | Acquired (bat lyssavirus, raccoon variant - bite, scratch, mucosal contact) | N/A | N/A | Same as classical rabies; bat exposures may go unrecognized | All ages | Exposure history (bat in room), RT-PCR, IFA on brain biopsy | PEP for any unprovoked wildlife bite, all bat exposures, vaccine + RIG | No | A82.0 | N/A | Central nervous system | Severe | Reduced |
| 3 | 3 | Australian Bat Lyssavirus (ABLV) | Viral Zoonosis | Rare; Australia (flying foxes, microbats) | Acquired (ABLV - bat bite/scratch) | N/A | N/A | Rabies-like encephalitis, uniformly fatal; only 3 reported human cases | All ages | RT-PCR, IFA, serology | Standard rabies PEP (vaccine + HRIG), supportive ICU | No | A82.0 | N/A | Central nervous system | Severe | Reduced (fatal) |
| 4 | 4 | European Bat Lyssavirus (EBLV-1/2) | Viral Zoonosis | Rare; Europe (Serotine and Daubenton's bats) | Acquired (EBLV - bat bite) | N/A | N/A | Rabies-like encephalitis, fatal | All ages | RT-PCR, IFA | Rabies PEP (cross-protective vaccine), supportive | No | A82.0 | N/A | Central nervous system | Severe | Reduced |
| 5 | 5 | Nipah Virus Encephalitis | Viral Zoonosis | Outbreaks in Bangladesh, India, Malaysia (~40-75% case fatality) | Acquired (Pteropus fruit bats - contaminated date palm sap, intermediate pigs, person-to-person) | N/A | N/A | Fever, headache, encephalitis, seizures, coma, ARDS; high mortality | All ages | RT-PCR (CSF, throat), IgM/IgG ELISA, virus isolation BSL-4 | Supportive ICU; ribavirin and monoclonal antibody (m102.4) experimental; isolation precautions | No | B33.8 | N/A | Central nervous system/Respiratory | Severe | Reduced |
| 6 | 6 | Ebola Virus Disease (Zaire ebolavirus) | Viral Hemorrhagic Fever | Recurrent outbreaks Central/West Africa; 2014 epidemic >28,000 cases | Acquired (fruit bat reservoir suspected, primates intermediate; direct contact with body fluids) | N/A | N/A | Sudden fever, severe headache, myalgia, vomiting/diarrhea, hemorrhage, shock, multi-organ failure (CFR 25-90%) | All ages | RT-PCR, antigen ELISA, IgM/IgG; BSL-4 | Supportive (fluids, electrolytes), monoclonal antibodies (Inmazeb, Ebanga), Ervebo vaccine (rVSV-ZEBOV) | Yes | A98.4 | N/A | Multisystem | Severe | Reduced |
| 7 | 7 | Marburg Virus Disease | Viral Hemorrhagic Fever | Sporadic outbreaks Africa; ~50% CFR (range 24-88%) | Acquired (Egyptian fruit bats; person-to-person via body fluids) | N/A | N/A | Severe hemorrhagic fever, similar to Ebola, mucosal bleeding, DIC, shock | All ages | RT-PCR, antigen ELISA, IgM/IgG; BSL-4 | Supportive only; investigational mAbs and vaccines (Sabin cAd3-Marburg) | Yes | A98.3 | N/A | Multisystem | Severe | Reduced |
| 8 | 8 | Lassa Fever | Viral Hemorrhagic Fever | 100,000-300,000 infections/yr in West Africa, ~5,000 deaths | Acquired (Mastomys natalensis multimammate rat - urine/feces, aerosol, person-to-person) | N/A | N/A | Insidious fever, malaise, sore throat, vomiting, hemorrhage in 20%, sensorineural hearing loss in survivors | All ages | RT-PCR, antigen detection, IgM ELISA; BSL-4 | Ribavirin (early), supportive care, ribavirin PEP for contacts; isolation | No | A96.2 | N/A | Multisystem | Severe | Variable |
| 9 | 9 | Crimean-Congo Hemorrhagic Fever (CCHF) | Viral Hemorrhagic Fever | Endemic Africa, Balkans, Middle East, Asia; CFR 10-40% | Acquired (Hyalomma ticks; livestock blood; person-to-person nosocomial) | N/A | N/A | Sudden fever, myalgia, headache, hemorrhage (petechiae, ecchymoses), hepatorenal failure | All ages | RT-PCR, IgM/IgG ELISA, virus isolation; BSL-4 | Ribavirin (efficacy debated), supportive ICU, strict barrier nursing | No | A98.0 | N/A | Multisystem | Severe | Variable |
| 10 | 10 | Rift Valley Fever | Viral Hemorrhagic Fever | Outbreaks Africa, Arabian Peninsula; case fatality <1% but severe forms 10-20% | Acquired (Aedes/Culex mosquitoes; ruminant blood/aerosol; aborted fetuses) | N/A | N/A | Mostly mild flu-like illness; severe forms: hemorrhagic fever, encephalitis, retinitis, hepatitis | All ages | RT-PCR, IgM ELISA, virus isolation | Supportive care; ribavirin investigational; veterinary vaccines; PPE for animal handlers | No | A92.4 | N/A | Multisystem | Variable | Variable |
| 11 | 11 | Hantavirus Pulmonary Syndrome (HPS) | Viral Hemorrhagic Fever | ~800 US cases since 1993; CFR ~38% | Acquired (Sin Nombre virus - deer mouse aerosolized excreta) | N/A | N/A | Prodrome (fever, myalgia) → cardiopulmonary phase (rapid ARDS, shock, cardiac depression) | All ages | Hantavirus IgM/IgG ELISA, RT-PCR, immunohistochemistry | Supportive ICU (ECMO, vasopressors); no specific antiviral; rodent control | No | B33.4 | N/A | Cardiopulmonary | Severe | Variable |
| 12 | 12 | Hemorrhagic Fever with Renal Syndrome (HFRS) | Viral Hemorrhagic Fever | ~150,000 cases/yr, mostly Asia (Hantaan, Seoul, Puumala) | Acquired (Old World hantaviruses - rodent excreta aerosol) | N/A | N/A | Fever, hypotension, oliguric AKI, hemorrhage, polyuric recovery; CFR 1-15% | All ages | Hantavirus IgM ELISA, RT-PCR | Supportive (dialysis, fluids); ribavirin (efficacy uncertain) | No | A98.5 | N/A | Renal/Hematologic | Severe | Variable |
| 13 | 13 | Yellow Fever | Viral Hemorrhagic Fever | ~200,000 cases, 30,000 deaths/yr (Africa, S America) | Acquired (Aedes aegypti; sylvatic primate reservoir) | N/A | N/A | Biphasic: fever, myalgia → remission → toxic phase (jaundice, hemorrhage, AKI, shock) | All ages | RT-PCR, IgM MAC-ELISA, PRNT (cross-reactivity with flaviviruses) | Supportive only; YF-17D live attenuated vaccine highly effective | No | A95.9 | N/A | Multisystem | Severe | Variable |
| 14 | 14 | Kyasanur Forest Disease (KFD) | Viral Hemorrhagic Fever | Endemic Karnataka, India (~400-500 cases/yr) | Acquired (Haemaphysalis ticks; monkeys/rodents reservoir) | N/A | N/A | Biphasic fever, headache, hemorrhage, neurological complications in second phase | All ages | RT-PCR, IgM/IgG ELISA, virus isolation | Supportive; killed vaccine available in endemic areas | No | A98.8 | N/A | Multisystem | Severe | Variable |
| 15 | 15 | Omsk Hemorrhagic Fever | Viral Hemorrhagic Fever | Endemic Siberia (Omsk, Novosibirsk) | Acquired (Dermacentor ticks; muskrat reservoir; direct contact with infected animals) | N/A | N/A | Fever, hemorrhage, papulovesicular rash; CFR 0.5-3% | All ages | RT-PCR, ELISA | Supportive only | No | A98.1 | N/A | Multisystem | Variable | Variable |
| 16 | 16 | Avian Influenza A(H5N1) HPAI | Zoonotic Influenza | ~900 human cases since 2003; CFR ~50% (WHO) | Acquired (infected poultry, wild birds; rare mammalian spillover) | N/A | N/A | Severe pneumonia, ARDS, multi-organ failure, lymphopenia, encephalopathy in some | All ages | RT-PCR (subtype-specific), viral culture BSL-3, paired serology | Oseltamivir (early), baloxavir; supportive ICU; H5N1 vaccines stockpiled | No | J09.X1 | N/A | Respiratory | Severe | Reduced |
| 17 | 17 | Avian Influenza A(H7N9) | Zoonotic Influenza | >1,500 human cases (China, 2013-); CFR ~39% | Acquired (live poultry market exposure) | N/A | N/A | Severe pneumonia, ARDS, secondary bacterial infection | Adults predominantly | RT-PCR (H7 and N9 specific), culture | Oseltamivir; supportive; H7N9 vaccines | No | J09.X1 | N/A | Respiratory | Severe | Reduced |
| 18 | 18 | Avian Influenza A(H5N6, H9N2, H7N7) | Zoonotic Influenza | Sporadic spillover; variable severity | Acquired (poultry contact) | N/A | N/A | Mild conjunctivitis to severe pneumonia depending on subtype | All ages | RT-PCR subtyping | Oseltamivir, supportive care | No | J09.X9 | N/A | Respiratory | Variable | Variable |
| 19 | 19 | Swine Influenza A(H1N1v / H3N2v) | Zoonotic Influenza | Sporadic outbreaks at agricultural fairs (US) | Acquired (pigs - direct contact) | N/A | N/A | Fever, cough, sore throat; usually mild but can be severe | All ages (children at fairs) | RT-PCR (variant subtyping) | Oseltamivir, supportive | No | J10.1 | N/A | Respiratory | Variable | Normal |
| 20 | 20 | SARS (SARS-CoV) | Zoonotic Coronavirus | 2002-2003 outbreak: 8,096 cases, 774 deaths (CFR ~10%) | Acquired (bat origin via masked palm civet intermediate; person-to-person droplet) | N/A | N/A | Fever, dry cough, dyspnea, ARDS, watery diarrhea | All ages | RT-PCR, paired serology | Supportive ICU; no specific antiviral proven; remdesivir tested in vitro | No | J12.81 | N/A | Respiratory | Severe | Variable |
| 21 | 21 | MERS-CoV (Middle East Respiratory Syndrome) | Zoonotic Coronavirus | >2,600 cases since 2012; CFR ~35% | Acquired (dromedary camel reservoir; nosocomial human-to-human) | N/A | N/A | Severe pneumonia, ARDS, AKI; high mortality in elderly/comorbid | Adults predominantly | RT-PCR (upper + lower respiratory), serology | Supportive ICU; investigational mAbs; convalescent plasma | No | B34.2 | N/A | Respiratory | Severe | Reduced |
| 22 | 22 | COVID-19 (SARS-CoV-2) | Zoonotic Coronavirus | Global pandemic since 2019; >700M reported cases | Acquired (likely bat origin; respiratory droplets/aerosol; sustained human-to-human) | N/A | N/A | Spectrum from asymptomatic to ARDS, thromboembolism, multi-organ failure, post-acute sequelae | All ages (severe in elderly/comorbid) | RT-PCR, antigen tests, serology | mRNA/vector vaccines; nirmatrelvir/ritonavir, remdesivir, dexamethasone, tocilizumab; oxygen/ICU | No | U07.1 | N/A | Respiratory/Multisystem | Variable | Variable |
| 23 | 23 | Mpox (Monkeypox) | Viral Zoonosis | 2022 multi-country outbreak >90,000 cases; endemic Central/West Africa | Acquired (rodent reservoir, primates; close contact, sexual transmission, fomites) | N/A | N/A | Fever, lymphadenopathy, vesiculopustular rash (centrifugal), proctitis in MSM cluster | All ages | RT-PCR (lesion swab), histopathology | Tecovirimat (TPOXX), brincidofovir; JYNNEOS vaccine; supportive | Yes | B04 | N/A | Skin/Multisystem | Variable | Variable |
| 24 | 24 | Hendra Virus Infection | Viral Zoonosis | Rare; Australia (flying foxes → horses → humans) | Acquired (Pteropus bats → equine intermediate) | N/A | N/A | Influenza-like illness → encephalitis or pneumonia; CFR ~57% | Adults | RT-PCR, IgM/IgG, virus isolation BSL-4 | Supportive; m102.4 mAb experimental | No | B33.8 | N/A | Respiratory/CNS | Severe | Reduced |
| 25 | 25 | Lymphocytic Choriomeningitis (LCMV) | Viral Zoonosis | Worldwide; mostly mild; severe in immunocompromised, fetus | Acquired (house mouse Mus musculus, hamsters - aerosol/direct contact) | N/A | N/A | Biphasic febrile illness ± aseptic meningitis; congenital infection: hydrocephalus, chorioretinitis | All ages (severe in fetus, transplant recipients) | IgM/IgG serology, RT-PCR, CSF analysis | Supportive; ribavirin for severe cases | No | A87.2 | N/A | Central nervous system | Variable | Variable |
- Full dataset access
- Excel format
- Instant download